Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb

Having gained rights to Incyte’s PD-1 inhibitor, Zai rolled out an immuno-oncology combination strategy it thinks can carve out a space in the crowded Chinese checkpoint inhibitor field.

Zai Lab Ltd. (NASDAQ:ZLAB) licensed exclusive rights to anti-PD-1 mAb INCMGA0012 from Incyte Corp. (NASDAQ:INCY) in China, Hong Kong, Macao and Taiwan. Incyte will receive

Read the full 520 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE